Return to search results.
Complete title: A Phase 1, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZ8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamoous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-Deficient Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZ8186 with Prospectively-validated PTEN-deficient Tumors
|Research Study Number||20131275|
|Principal Investigator||Tia Higano, MD|
Research Study Description
There are two parts to this study: Part A, dose escalation, and Part B, expansion cohort(s) at the intended therapeutic dose(s).
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Breast Cancer; Genitourinary Cancer; Lung Cancer; Prostate Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.